ADAR1 Capital Management LLC Increases Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

ADAR1 Capital Management LLC lifted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 35.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 146,671 shares of the company's stock after buying an additional 38,500 shares during the period. ADAR1 Capital Management LLC's holdings in Teva Pharmaceutical Industries were worth $3,233,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Oarsman Capital Inc. purchased a new position in Teva Pharmaceutical Industries during the fourth quarter worth $29,000. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries in the third quarter worth about $50,000. Ameliora Wealth Management Ltd. purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $66,000. IFP Advisors Inc boosted its stake in shares of Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after purchasing an additional 1,960 shares during the period. Finally, Quadrant Capital Group LLC boosted its position in Teva Pharmaceutical Industries by 27.7% in the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after buying an additional 949 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Friday, April 4th. Bank of America cut their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. Barclays lowered their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Finally, UBS Group cut their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and an average price target of $23.43.

Remove Ads

Teva Pharmaceutical Industries Stock Up 4.7 %

NYSE:TEVA traded up $0.60 during midday trading on Friday, reaching $13.42. 12,222,912 shares of the stock traded hands, compared to its average volume of 9,939,000. The business has a 50-day moving average of $15.79 and a two-hundred day moving average of $17.82. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The stock has a market capitalization of $15.22 billion, a PE ratio of -9.26, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.